Mankind Pharma Limited MANKIND NIFTY_MIDNSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India

https://www.mankindpharma.com

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboon, Gudcef, Candi Force, Glimestar-M, Telmikind-Am, Nurokind-Gold, Telmikind-H, Nurokind-Lc, Telmikind, Vomikind, Cefakind, Nurokind Plus-Rf, Gudcef-Cv, Monticope, and Asthakind-Dx brand names. Mankind Pharma Limited was incorporated in 1991 and is based in New Delhi, India.

Market & Price

Market Cap

₹98,090.71 Cr

Current Price

₹2,375.60

High / Low (52W)

₹2,695.44 / ₹1,927.40

Beta

0.47

Valuation

Stock P/E

51.29

Industry PE

37.60

Forward P/E

33.06

PEG Ratio

Book Value

₹370.26

Price to Book

6.42

P/S

6.87

EV/EBITDA

28.28

Dividend Yield

0.08%

Profitability & Returns

ROCE

13.78%

ROE

12.45%

ROA

6.11%

Profit Margin

13.40%

Op Margin

20.56%

EPS (Latest Qtr)

₹13.41

EPS (TTM)

₹46.32

Balance Sheet & Liquidity

Debt/Equity

0.38

Quick Ratio

0.61

Current Ratio

1.07

Debt

₹6,311.54 Cr

Total Assets

₹28,079.53 Cr

Current Assets

₹6,954.20 Cr

Working Capital

₹446.95 Cr

Ownership

Promoter Holding

75.41%

Chg in Prom Hold

FII / Inst Holding

19.60%

Chg in FII Hold

Financial Snapshot

Enterprise Value

₹1.02 L Cr

Total Revenue (TTM)

₹14,277.64 Cr

EBITDA

₹3,617.41 Cr

Free Cash Flow

₹1,647.91 Cr

Operating Cash Flow

₹3,121.29 Cr

Shares Outstanding

₹41.29 Cr

Gross Margin

71.62%

Payout Ratio

2.16%

Growth (CAGR)

Revenue 5Y

17.73%

Profit 5Y

14.28%

Revenue (YoY)

11.80%

Earnings (YoY)

31.70%

PROS

Compounding revenue at 17.7% over 5 years.
Profit CAGR of 14.3% over 5 years.
Generates positive free cash flow.

CONS

Trading at a high P/E of 51.3.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

NSE TradingView Screener.in

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA	2,375.60	51.29	₹98,090.71 Cr	0.08%	13.78%	12.45%	17.73%	14.28%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,799.20	37.59	₹4.32 L Cr	0.92%	17.94%	14.72%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	6,667.00	68.97	₹1.77 L Cr	0.45%	18.96%	16.19%	11.27%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,410.80	68.96	₹1.49 L Cr	0.86%	9.06%	16.98%	13.27%	20.21%
5	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,401.00	29.16	₹1.13 L Cr	0.93%	14.88%	11.74%	7.23%	11.45%
6	DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA	1,303.50	25.90	₹1.09 L Cr	0.61%	14.00%	11.83%	10.96%	-2.35%
7	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,077.70	21.51	₹1.08 L Cr	0.09%	19.24%	18.32%	16.55%	36.99%
8	LUPIN Lupin Limited NIFTY_MIDNSEPHARMA	2,267.70	19.49	₹1.04 L Cr	0.53%	28.42%	26.91%	19.10%	131.46%
9	MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA	965.10	65.34	₹93,927.75 Cr	0.16%	12.70%	14.33%	23.10%	9.34%

Quarterly Results

Figures in INR.

Metric	Dec 2024	Mar 2025	Jun 2025	Dec 2025	Mar 2026
Revenue	3,198.79 Cr	3,079.37 Cr	3,570.35 Cr	3,567.20 Cr	3,442.93 Cr
Cost of Revenue	931.51 Cr	875.38 Cr	1,053.59 Cr	977.99 Cr	958.37 Cr
Gross Profit	2,267.28 Cr	2,203.99 Cr	2,516.76 Cr	2,589.21 Cr	2,484.56 Cr
Operating Expenses	1,638.46 Cr	1,751.67 Cr	1,888.67 Cr	1,892.38 Cr	1,777.76 Cr
Operating Income	628.82 Cr	452.32 Cr	628.09 Cr	696.83 Cr	706.80 Cr
EBITDA	896.43 Cr	936.84 Cr	929.82 Cr	888.80 Cr	1,024.00 Cr
Interest Expense	220.93 Cr	190.54 Cr	170.65 Cr	157.20 Cr	141.75 Cr
Pretax Income	488.33 Cr	515.43 Cr	540.49 Cr	509.00 Cr	659.17 Cr
Tax Provision	110.46 Cr	86.44 Cr	95.87 Cr	95.12 Cr	99.75 Cr
Net Income	380.23 Cr	420.77 Cr	438.32 Cr	408.75 Cr	554.35 Cr
Diluted EPS	9.44	10.18	10.60	9.89	13.41

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	-	8,749.43 Cr	10,259.29 Cr	12,207.44 Cr	14,277.64 Cr
Cost of Revenue	-	2,962.33 Cr	3,257.31 Cr	3,489.04 Cr	4,052.12 Cr
Gross Profit	-	5,787.11 Cr	7,001.98 Cr	8,718.40 Cr	10,225.52 Cr
Operating Expenses	-	4,145.49 Cr	4,762.71 Cr	6,321.69 Cr	7,494.29 Cr
Operating Income	-	1,641.62 Cr	2,239.27 Cr	2,396.71 Cr	2,731.23 Cr
EBITDA	-	2,037.43 Cr	2,824.01 Cr	3,566.96 Cr	3,858.14 Cr
Interest Expense	-	40.27 Cr	27.82 Cr	429.41 Cr	639.28 Cr
Pretax Income	-	1,671.24 Cr	2,397.94 Cr	2,516.33 Cr	2,332.68 Cr
Tax Provision	-	361.56 Cr	457.15 Cr	509.74 Cr	394.58 Cr
Net Income	-	1,281.86 Cr	1,912.90 Cr	1,990.96 Cr	1,912.93 Cr
Diluted EPS	35.78	32.00	47.68	49.19	-

Compounded Sales Growth

5 Years:	17.73%
1 Year:	11.80%

Compounded Profit Growth

5 Years:	14.28%
1 Year:	31.70%

Stock Price Performance

1 Year:	-3.46%
6 Months:	+6.88%
3 Months:	+16.08%
1 Month:	+5.26%

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	-	9,715.45 Cr	11,963.25 Cr	27,759.53 Cr	28,079.53 Cr
Current Assets	-	4,327.87 Cr	6,568.22 Cr	6,988.27 Cr	6,954.20 Cr
Cash & Equivalents	-	304.82 Cr	382.01 Cr	407.36 Cr	391.69 Cr
Inventory	-	1,498.46 Cr	1,553.46 Cr	2,093.71 Cr	2,144.48 Cr
Receivables	-	576.42 Cr	848.28 Cr	1,538.34 Cr	1,729.51 Cr
Total Liabilities	-	2,092.16 Cr	2,387.46 Cr	13,191.35 Cr	11,518.48 Cr
Current Liabilities	-	1,863.14 Cr	2,119.73 Cr	5,663.56 Cr	6,507.25 Cr
Long Term Debt	-	23.15 Cr	24.87 Cr	5,526.19 Cr	2,821.23 Cr
Total Debt	-	170.37 Cr	207.17 Cr	8,511.45 Cr	6,311.54 Cr
Total Equity	-	7,435.22 Cr	9,363.09 Cr	14,332.39 Cr	16,300.34 Cr
Shares Outstanding	-	40.06 Cr	40.06 Cr	41.26 Cr	41.28 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	-	1,813.30 Cr	2,152.44 Cr	2,413.38 Cr	3,121.29 Cr
Investing Cash Flow	-	-1,054.13 Cr	-2,081.69 Cr	-12,682.95 Cr	-196.42 Cr
Financing Cash Flow	-	-739.73 Cr	5.27 Cr	10,232.56 Cr	-2,952.69 Cr
Capital Expenditure	-	-832.07 Cr	-389.21 Cr	-520.11 Cr	-737.24 Cr
Free Cash Flow	-	981.23 Cr	1,763.23 Cr	1,893.27 Cr	2,384.05 Cr
Net Change in Cash	-	19.44 Cr	76.02 Cr	-46.41 Cr	-27.82 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	66.1%	68.3%	71.4%	71.6%
Operating Margin %	-	18.8%	21.8%	19.6%	19.1%
Net Margin %	-	14.7%	18.6%	16.3%	13.4%
ROE %	-	17.2%	20.4%	13.9%	11.7%
ROCE %	-	20.9%	22.7%	10.8%	12.7%

Shareholding Pattern

Insiders

75.41%

Institutions

19.60%

Public Float

79.73%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MANKIND

No recent headlines available.

MANKIND · Healthcare